Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
CONTESSA: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane O'Shaughnessy, J., Piccart, M., Schwartzberg, L., Cortes, J., Harbeck, N., Im, S., Rugo, H., Untch, M., Yardley, D., Bondarenko, I., Dieras, V., Pegram, M., Kroll, S., O'Connell, J., Vacirca, J., Wei, T., Tang, K., Seidman, A. AMER ASSOC CANCER RESEARCH. 2020
View details for DOI 10.1158/1538-7445.SABCS19-OT1-08-09
View details for Web of Science ID 000527012500104